Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pathophysiological-based treatments of complications of cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Telemedicin til monitorering af inflammatoriske tarmsygdomme og colon irritabile

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dietary risk factors for inflammatory bowel diseases in a high-risk population: Results from the Faroese IBD study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Ethnic differences in inflammatory bowel disease: Results from the United Kingdom inception cohort epidemiology study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sarah Alulis
  • Kasper Vadstrup
  • Andras Borsi
  • Agnete Nielsen
  • Tine Rikke Jørgensen
  • Niels Qvist
  • Pia Munkholm
Vis graf over relationer

Background: The choice of treatment for Crohn's disease (CD) and ulcerative colitis (UC) depends among other factors, disease severity. Patients with moderate-to-severe disease should be prescribed biologic response modifiers (biologics), according to guidelines. This study aims to explore the treatment patterns of patients diagnosed with CD and UC between 2003 and 2015 that were treated with biologics in Denmark between the years 2003 and 2016.Methods: This national register study included patients diagnosed between 2003 and 2015, identified in the Danish National Patient Registry. Biologic therapies available during the study period were infliximab, adalimumab, vedolizumab and golimumab. The share of patients initiating and receiving biologic treatment in each year was estimated. Additionally, the time from IBD diagnosis to first biologic treatment and time between treatments was calculated.Results: Among 10,302 CD patients and 22,144 UC patients, 28.5% of CD patients and 11.3% of UC patients received treatment with biologics during the study period, with an increasing trend in the number of patients initiating treatment with biologics each year. About 46% of CD patients and 45% of UC patients received their first biologic treatment within the first year after IBD diagnosis. About 57-68% of CD and UC patients received treatment with their second line biologic within 2 months of the last treatment of their first line.Conclusions: The number of patients initiating biologic treatments after diagnosis increased throughout the study period. Most patients diagnosed with CD and UC are receiving biologic treatments relatively soon after their diagnosis.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Sider (fra-til)1-7
Antal sider7
ISSN0036-5521
DOI
StatusE-pub ahead of print - 2 mar. 2020

ID: 59596971